NF-κB

International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma

Retrieved on: 
Tuesday, November 21, 2023
Quality of life, Lung cancer, PVD, Survival, NF-κB, BRAF, Research, Bromodeoxyuridine, Melanoma, SH-4, Incidence, Factorization of polynomials, Cancer, COX2, MTT, Neoplasm, STAT, ATP, Enzyme, Manuscript, Cell, Patient, Agonal respiration, Canadian International Council, Vaccine

BERWYN, PA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, today announced publication of positive data in the peer-reviewed International Journal of Molecular Sciences in a manuscript titled, “In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes.”1 The publication by Gambichler, et al. (2023) details the anti-tumor activity of the GAPDH inhibitor misetionamide (GP-2250) in BRAF-mutated melanoma cell lines and benign melanocytes. Mutated BRAF is a potent oncogene involved in sending signals inside cells which are involved in directing cell growth and is overexpressed in melanomas, non-small cell lung cancer, and other tumor types.

Key Points: 
  • (2023) details the anti-tumor activity of the GAPDH inhibitor misetionamide (GP-2250) in BRAF-mutated melanoma cell lines and benign melanocytes.
  • Results of this preclinical study showed misetionamide has anti-neoplastic effects in BRAF-mutated melanoma cell lines regarding tumor cell viability, proliferation, and apoptosis/necrosis.
  • The team studied three melanoma cell lines and one primary melanocyte cell line (Ma-Mel-61a, Ma-Mel-86a, SH-4, and ATCC-PCS-200-013, respectively) which were exposed to different misetionamide doses.
  • “We are very excited to see the cancer cell killing benefits of misetionamide demonstrated in this study.

Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Friday, November 3, 2023
TNFRSF, NF-κB, Hook effect, CD70, Kineta, SITC, Immunotherapy, NK, Antibody, Annual general meeting, Society, Cancer, CD27, Vaccine, Pharmaceutical industry

SEATTLE, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new preclinical data on the company’s anti-CD27 agonist monoclonal antibodies (mAbs) at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster revealing new preclinical data.

Key Points: 
  • Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster revealing new preclinical data.
  • The lead agonist anti-CD27 mAbs demonstrated high affinity binding to both human and cynomolgus monkey CD27 and not to mouse CD27.
  • Additionally, they exhibited high specificity against CD27 with no cross-reactivity detected against other members of the tumor necrosis factor receptor superfamily (TNFRSF).
  • The strong agonist proprieties of the company’s lead anti-CD27 antibodies were further demonstrated on T cell proliferation and activation as well as NK cell activation.

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

Retrieved on: 
Monday, October 30, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Growth, RAS, NYSE, Food, Hope, Pathology, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, CANF, EMA, Pancreatic cancer, NF-κB, TASE, Safety, Hepatology, Apoptosis, Patient, Death, Cancer, Pharmaceutical industry, WNT

The article includes a summary on the robust inhibition of pancreatic carcinoma growth, both in vitro and in vivo and a definitive description of the molecular mechanism of action.

Key Points: 
  • The article includes a summary on the robust inhibition of pancreatic carcinoma growth, both in vitro and in vivo and a definitive description of the molecular mechanism of action.
  • This mechanism is highly important since pancreatic carcinoma cells are resistant to the chemotherapy.
  • “We are very much encouraged by the excellent data in the pre-clinical studies demonstrating the impressive anti-cancer effect of Namodenoson against pancreatic carcinoma,” stated Dr. Fishman, Can-Fite’s Chief Scientific Officer and Executive Chairman.
  • “We plan to start treating patients very shortly and hope that Namodenoson, with its positive safety and efficacy profile, will prolong life for pancreatic cancer patients.”

HotSpot Therapeutics to Introduce First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
CBM, NF-κB, Non-Hodgkin lymphoma, IND, Biotechnology, Drug resistance, Multiple myeloma, Hotspot, Cell, Protein, Society, ASH, Lymphoid neoplasms with plasmablastic differentiation, Pharmacology, Bone marrow, Therapy, Manchester Grand Hyatt Hotel, Pharmaceutical industry, MALT1, Lymphoma

BOSTON, Nov. 2, 2023 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced it will present preclinical data from the Company's highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program in an oral presentation at the 2023 American Society of Hemotology (ASH) Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.

Key Points: 
  • MALT1 is a component of the CARD11-BCL10-MALT1 (CBM) protein complex, which serves as a key regulator of NFkB signaling in cells, including B and T cells.
  • MALT1 is implicated in a range of hematological malignancies, including Non-Hodgkin's lymphoma, as well as other lymphomas and selected solid tumors.
  • Leveraging our proprietary Smart Allostery™ platform, HotSpot has developed first-in-class small molecules designed to selectively inhibit the scaffolding function of MALT1, a dominant driver of the NFkB pathway.
  • This oral presentation will describe the differentiated preclinical profile for HotSpot's scaffolding inhibitor, including the potential for an improved efficacy and safety profile versus traditional MALT1 inhibitors that target protease function.

Muscular Dystrophy Association-Supported Drug AGAMREE® (vamorolone) Approved for the Treatment of Duchenne Muscular Dystrophy by the FDA

Retrieved on: 
Thursday, October 26, 2023
Steroid, Principal, FDA, Duke University Hospital, Research, University, NF-κB, Dean (education), Associate, Duke University, MDA, Diversified Pharmaceutical Services, Muscular Dystrophy Association, Binghamton University, Medical director, Rare disease, Weight gain, US Food Sovereignty Alliance, Doctor of Philosophy, Catalyst Pharmaceuticals, Vamorolone, Pediatrics, Disease, Clinical trial, Duchenne, Duchenne muscular dystrophy, DMD, Investment, Patient, Griffin, Bone density, Pharmaceutical industry, Nursing

New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique steroidal anti-inflammatory drug to treat children and adolescents living with Duchenne muscular dystrophy (DMD).

Key Points: 
  • New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique steroidal anti-inflammatory drug to treat children and adolescents living with Duchenne muscular dystrophy (DMD).
  • This multi-functional drug shows potent inhibition of pro-inflammatory NFkB pathways via high-affinity binding to the glucocorticoid receptor, high-affinity antagonism for the mineralocorticoid receptor, and membrane stabilization properties.
  • This novel therapy, supported in part by MDA Venture Philanthropy, demonstrates similar efficacy to traditional corticosteroids with reduced negative downstream impacts or side effects.
  • “My son was diagnosed with Duchenne muscular dystrophy, and he was the first person dosed with vamorolone right before his 7th birthday.

Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

Retrieved on: 
Wednesday, October 4, 2023
NF-κB, AACR, TNF, CD70, Hook effect, Cancer, American Association for Cancer Research, NK, Kineta, Patient, CD27, Mab, TNFRSF, Bone marrow, IND, Conference, Vaccine, Immunotherapy

Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, unveiled new preclinical data in the company’s poster titled “CD27 is a new promising T cell co-stimulatory target for cancer immunotherapy”.

Key Points: 
  • Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, unveiled new preclinical data in the company’s poster titled “CD27 is a new promising T cell co-stimulatory target for cancer immunotherapy”.
  • Strong agonist proprieties on T cell proliferation and activation after engagement of NFkB-mediated CD27 signaling as well as NK cell activation were also observed.
  • Importantly, the nominated lead mAb showed antitumor efficacy in vivo in solid and hematological mouse tumor models as a single agent or in combination with other immunotherapies.
  • CD27 is highly expressed on naïve T cells and also provides a co-stimulatory signal for NK cell activation.

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

Retrieved on: 
Tuesday, September 12, 2023
KRAS, Nanoparticle, Rhinitis, Marketing, Synovitis, Heqet, Allergic rhinitis, RNA, MBA, Doctor of Philosophy, Preprint, Patent, Patient, NF-κB, MITES, AVS, DNMT3B, Rheumatoid arthritis, Joint capsule, Therapy, Myocardial infarction, Research, Small RNA, Regeneration, Sneeze, Washington University School of Law, Neoplasm, Nasal spray, FDA, Vertigo, IND, Safety, Volunteering, SAR, Altamira, Cell, IP, Immunotherapy, Messenger, NASAR, Nasal congestion, CHF, Osteoarthritis Research Society International, Rhinorrhea, Q&A, SARS-CoV-2, Infection, Clinical trial, Pollen, Inflammation, ANCOVA, OTC, Mouse, Washington University School of Medicine, Vaccine, Pharmaceutical industry, Cryptocurrency, BPPV, St. Louis

Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.

Key Points: 
  • Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.
  • ET
    Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its first half 2023 financial results.
  • Net loss for the first half of 2023 was CHF 5.4 million compared with CHF 8.2 million for the first half of 2022.
  • ET to discuss its business update and first half 2023 results.

MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting

Retrieved on: 
Tuesday, May 16, 2023
Inflammation, Temperature, GH, Cryogenic electron microscopy, Endocrine gland, Risk, Cell, ALS, Virus, Gene, DSM-IV codes, Research, Gene expression, Ion, AUC, American Society of Gene and Cell Therapy, Liver, Neoplasm, AAV2, Kinetics, Death, Poster, HPLC, Genome, Safety, Neuron, Growth hormone, Muscular dystrophy, STR, Transfection, AAV, Hepatocyte, CAR, Sequence, Animal, CMV, Immune system, Cancer, AEX, Plasmid, PH, Neurological disorder, Human, NF-κB, Riboswitch, LDH, DSW, RNA, Skeletal muscle, CAG, Sure, Annual general meeting, Mouse, Society, FTD, Vaccine, Publication

RiboCAR is a synthetic riboswitch-based gene regulation system for precise regulation of CAR expression levels in CAR-T cell therapy via orally available small molecule.

Key Points: 
  • RiboCAR is a synthetic riboswitch-based gene regulation system for precise regulation of CAR expression levels in CAR-T cell therapy via orally available small molecule.
  • We demonstrate that with a bioavailable small molecule inducer, CAR-T activity can be precisely tuned and “remotely” controlled in vivo.
  • However, excessive amounts of transgene from unregulated vectors may limit the breadth of applicability of gene therapy.
  • Collectively, these results show we have established a robust platform to screen engineered promoters for applications to skeletal muscle gene therapies.

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

Retrieved on: 
Wednesday, March 8, 2023
Immunotherapy, Stanford University, Literature, Bone marrow, Therapy, Laboratory, University of Pennsylvania, Oncology, SAB, BS, Memorial Sloan Kettering Cancer Center, Internal medicine, Patient, Pharmacology, Translation, MUC1, Fordham University, United States Air Force Scientific Advisory Board, MD, ETH Zurich, Massachusetts Institute of Technology, Harvard Medical School, Cell, History of the University of Maryland, College Park, University, Biosensor, Harvard University, Doctor of Philosophy, Glycosylation, Chromatin, NF-κB, LSE, Research, Hematology, CAR, Cell engineering, UMBC, Aptamer, Management, Vaccine, Biology, Genetics, Medicine, Chemistry, Biochemistry

“With the formation of our Scientific Advisory Board, we are expanding the depth and breadth of our leadership team and scientific expertise with the next generation of leaders in the field of gene and cell therapy,” said Doug Doerfler, President and CEO of MaxCyte.

Key Points: 
  • “With the formation of our Scientific Advisory Board, we are expanding the depth and breadth of our leadership team and scientific expertise with the next generation of leaders in the field of gene and cell therapy,” said Doug Doerfler, President and CEO of MaxCyte.
  • Supported by deep technical knowledge, the SAB will help us unlock the power of cells, which will enhance our R&D activities and portfolio,” said Cenk Sumen, PhD, Chief Scientific Officer of MaxCyte.
  • Dr. Maus holds graduate degrees (M.D., Ph.D.) from University of Pennsylvania, where she completed graduate training with Dr. Carl June.
  • Her thesis exploited aptamers to overcome the conventional bottlenecks of electronic biosensing of small molecules in complex biological environments.

Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 12, 2022
NF-κB, Annual report, Security (finance), ASH, Memorial Sloan Kettering Cancer Center, COVID-19, IRF4, B-cell lymphoma, Disease, Safety, Biotechnology, Skin, Cutaneous T cell lymphoma, Boston, Boston Business Journal, Risk, Society, Lymphatic system, Therapy, MDM2, PDX, Immunomodulatory imide drug, CTCL, MYD88, Pathology, Apoptosis, Patient, Science, CDX, STAT3, DLBCL, Vaccine, Pharmaceutical industry, Black Majesty, Medicine, IRAK4

WATERTOWN, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that preclinical data from collaborations for its STAT3 and IRAKIMiD degraders was presented at the American Society of Hematology (ASH) Annual Meeting, taking place from December 10 - 13, 2022 in New Orleans, Louisiana.

Key Points: 
  • The model was used to evaluate the therapeutic potential of one of Kymera’s potent and selective STAT3 heterobifunctional degraders for targeting this difficult-to-treat hematologic malignancy.
  • A single intravenous infusion of a STAT3 degrader led to substantial reduction in STAT3 levels in lymph node T cells, circulating T cells, and skin-resident T cells.
  • These data provide a rationale for selective STAT3 degradation as a therapeutic strategy for T cell malignancies such as CTCL that are associated with constitutive activation of STAT3 signaling.
  • Kymera’s lead STAT3 degrader, KT-333, is currently being evaluated in a Phase 1 clinical trial in liquid and solid tumors, including CTCL.